Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study
Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...
NYSE: NVO
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard
Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...
Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...
Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Belgium Bans Ozempic for Weight Loss as Global Shortage Persists
Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes...
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing...
Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform
Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...
Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases
Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...
Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at...
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a...
Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...
Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases
Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...
Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million
Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk...
Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic...
Weight-Loss Drug Demand Pushes Novo Nordisk to Peak European Market Capitalization
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) achieved a significant milestone last week when it...
Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents
Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness...